- Home
- MDRR vs ATHA Comparison
MDRR vs ATHA Comparison
Compare MDRR & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- ATHA
- Stock Information
- Founded
- MDRR 2015
- ATHA 2011
- Country
- MDRR United States
- ATHA United States
- Employees
- MDRR N/A
- ATHA N/A
- Industry
- MDRR Real Estate Investment Trusts
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- MDRR Real Estate
- ATHA Health Care
- Exchange
- MDRR Nasdaq
- ATHA Nasdaq
- Market Cap
- MDRR 15.8M
- ATHA 14.8M
- IPO Year
- MDRR 2018
- ATHA 2020
- Fundamental
- Price
- MDRR $12.72
- ATHA $0.39
- Analyst Decision
- MDRR
- ATHA Hold
- Analyst Count
- MDRR 0
- ATHA 3
- Target Price
- MDRR N/A
- ATHA $0.50
- AVG Volume (30 Days)
- MDRR 6.1K
- ATHA 99.8K
- Earning Date
- MDRR 08-07-2025
- ATHA 08-07-2025
- Dividend Yield
- MDRR 2.12%
- ATHA N/A
- EPS Growth
- MDRR N/A
- ATHA N/A
- EPS
- MDRR N/A
- ATHA N/A
- Revenue
- MDRR $9,649,145.00
- ATHA N/A
- Revenue This Year
- MDRR N/A
- ATHA N/A
- Revenue Next Year
- MDRR N/A
- ATHA N/A
- P/E Ratio
- MDRR N/A
- ATHA N/A
- Revenue Growth
- MDRR N/A
- ATHA N/A
- 52 Week Low
- MDRR $9.55
- ATHA $0.22
- 52 Week High
- MDRR $15.00
- ATHA $3.34
- Technical
- Relative Strength Index (RSI)
- MDRR 65.03
- ATHA 48.58
- Support Level
- MDRR $10.24
- ATHA $0.38
- Resistance Level
- MDRR $12.50
- ATHA $0.41
- Average True Range (ATR)
- MDRR 0.51
- ATHA 0.02
- MACD
- MDRR 0.13
- ATHA -0.00
- Stochastic Oscillator
- MDRR 98.94
- ATHA 34.05
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.